Abbott Laboratories (NYSE:ABT) stock is currently pricing at roughly $43.60. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 11 analysts covering the company at $48.00. That suggests shares of the stock may have another 9 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $52.00, which would imply another 81 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 6 “Buy” ratings in place. At the same time, 6 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 5 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.
Analysts at Edward Jones took a look at ABT shares in a research note released on Jun 21, 2016, and issued a Buy rating to this company. Morgan Stanley analysts provided their own take on company recently as well. In a research note published on Jan 04, 2016,the house assigned a Equal-Weight rating to this stock. According to a piece that hit the wires on Nov 13, 2015, researchers at Goldman reconsidered their prior rating on the stock, and lowered it from Buy Perform to Neutral.
Abbott Laboratories (ABT) Cap Table Analysis
Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 0.02 percent of the stock.
If we take a more granular look, White Miles D is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 3,143,077 shares, representing a total current market value of roughly $137038157.2. Eric S. Fain,M.D. is another major player among company insiders, currently holding 544,052 shares as of less than 0.1%, carrying a current market value of $23720667.2. Thomas C. Freyman is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 395,819 shares, valued at around $17257708.4 as of recent close.
We noted a few insider transactions for the stock recently as well.
In a transaction on 2017-04-27, the company’s Senior Vice President BIRD ROGER sold 5,600 company shares for 245390. That means, once accounting for this transaction, the Senior Vice President is left with a stake of 51,313 shares, carrying a current total market value of $2237247. In addition, by means of a transaction dated 2017-04-26, Senior Vice President MANNING JOSEPH J sold 4,200 shares worth $184590. After that transaction, this investor is left with a total holding of 22,024 shares, representing a total investment value of $960246.4. We also noted a 2017-03-31 transaction in which ABT Senior Vice President Contreras Jaime sold 767 shares at a stock price of $44.64, carrying a total value of $34240, after which, this insider’s investment stands at 124,148 shares, with an overall financial value of $5412853.
Abbott Laboratories (NYSE:ABT) Earnings View
In the company’s last quarter, ABT EPS moved to $0.48 from $0.65 compared sequentially with the prior quarter. Revenues for the company came in at $6.34BM. This stacks up against $5.33BM, on a sequential basis.
How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $0.43 per share on $6.15BM in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $0.60 to $0.61. On a year-over-year basis, that compares with an EPS comp of $0.55.